These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29463526)

  • 61. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
    Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort.
    Chen R; Wang J; Tang S; Zhang Y; Lv X; Wu S; Xia Y; Deng P; Ma Y; Tu D; Chen D; Zhan S
    Tuberculosis (Edinb); 2015 Jan; 95(1):68-74. PubMed ID: 25498879
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system.
    Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A
    mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
    Smythe W; Merle CS; Rustomjee R; Gninafon M; Lo MB; Bah-Sow O; Olliaro PL; Lienhardt C; Horton J; Smith P; McIlleron H; Simonsson US
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4164-71. PubMed ID: 23774436
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.
    Naftalin CM; Verma R; Gurumurthy M; Lu Q; Zimmerman M; Yeo BCM; Tan KH; Lin W; Yu B; Dartois V; Paton NI
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739782
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.
    van den Elsen SHJ; Sturkenboom MGG; Van't Boveneind-Vrubleuskaya N; Skrahina A; van der Werf TS; Heysell SK; Mpagama S; Migliori GB; Peloquin CA; Touw DJ; Alffenaar JC
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30373800
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association of genetic polymorphisms of
    Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
    BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013.
    Xia H; Zheng Y; Liu D; Wang S; He W; Zhao B; Song Y; Ou X; Zhou Y; van den Hof S; Cobelens F; Zhao Y
    Microbiol Spectr; 2021 Dec; 9(3):e0040921. PubMed ID: 34851179
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
    Seifert M; Capparelli E; Catanzaro DG; Rodwell TC
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085512
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Dooley K; Flexner C; Hackman J; Peloquin CA; Nuermberger E; Chaisson RE; Dorman SE
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4037-42. PubMed ID: 18765687
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial.
    Perumal R; Padayatchi N; Yende-Zuma N; Naidoo A; Govender D; Naidoo K
    Clin Infect Dis; 2020 Jan; 70(1):90-98. PubMed ID: 30809633
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
    Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
    Zvada SP; Denti P; Sirgel FA; Chigutsa E; Hatherill M; Charalambous S; Mungofa S; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2014; 58(1):503-10. PubMed ID: 24189253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
    van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.
    Chigutsa E; Visser ME; Swart EC; Denti P; Pushpakom S; Egan D; Holford NH; Smith PJ; Maartens G; Owen A; McIlleron H
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4122-7. PubMed ID: 21709081
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin.
    Weiner M; Burman W; Luo CC; Peloquin CA; Engle M; Goldberg S; Agarwal V; Vernon A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2861-6. PubMed ID: 17517835
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
    de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
    Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.